Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 and Pembrolizumab in HER2-overexpressing NSCLC
NCT07264816Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M07D1 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Biokin Pharmaceutical. Started Feb 2026; status: recruiting.
02
Drugs
BL-M07D1
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07264816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264816.